We are live on ! Find out more

Capricor Therapeutics

CAPR

Market cap $585M

10.06 USD

+0.70

7.48%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

10.08

+0.02

0.2%

1 day

7.48%

5 days

47.72%

1 month

43.71%

3 months

-65.48%

6 months

-63.98%

Year to date

-64.46%

1 year

60.96%

5 years

140.1%

10 years

-70.15%

About: Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Employees: 231

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 2.4%

Neutral 93.9%

Negative 3.7%

ROSEN, A NATIONALLY RECOGNIZED LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

New York, New York--(Newsfile Corp. - August 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline. SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A NATIONALLY RECOGNIZED LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

DEADLINE ALERT for RXT, CAPR, BE, PRCT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

DEADLINE ALERT for RXT, CAPR, BE, PRCT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (CAPR) to a Securities Class Action Deadline - Contact the Firm Before September 28, 2026

New York, New York--(Newsfile Corp. - August 27, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us.

Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (CAPR) to a Securities Class Action Deadline - Contact the Firm Before September 28, 2026

Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR

NEW ORLEANS, Aug. 27, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR), if they purchased Capricor securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.

Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR

CAPR DEADLINE: SueWallSt Reminds Capricor Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline

Capricor's Chief Executive Officer and Chief Financial Officer are named as individual defendants in a securities class action alleging they controlled and certified public statements about the HOPE-3 trial that allegedly omitted unagreed changes to the study's pre-specified statistical analysis plan. NEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt alerts investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a pending securities class action brought on behalf of shareholders who purchased securities between December 17, 2025 and July 26, 2026.

CAPR DEADLINE: SueWallSt Reminds Capricor Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline

CAPR Stock Alert: Capricor Therapeutics, Inc. Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman

San Francisco, California--(Newsfile Corp. - August 27, 2026) - National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Following Capricor's recent Q2 2026 earnings release and conference call—notable for an omission of management Q&A with analysts—the company is facing uncertainty amid an active securities fraud class action.

CAPR Stock Alert: Capricor Therapeutics, Inc. Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman

Capricor Therapeutics, Inc. (CAPR) Class Action Lawsuit Seeks Recovery for Investors; September 28, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summary Who: Capricor Therapeutics, Inc. (NASDAQ: CAPR) What: Securities fraud class action lawsuit filed Class Period: December 17, 2025 through July 26, 2026 Deadline to Seek Lead Plaintiff Status: September 28, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead product candidates statistical analysis plan and FDA compliance Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa.

Capricor Therapeutics, Inc. (CAPR) Class Action Lawsuit Seeks Recovery for Investors; September 28, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

See News Rankings

Price charts implemented using Lightweight Charts™